



Date: September 19, 2018

To: Medicaid and CHIP Managed Care Organizations

From: Texas Vendor Drug Program

Subject: N-18-004: Reminder: EpiPen and Authorized Generics Drug Shortages

The U.S. Food and Drug Administration has not published an update to their [Drug Shortages website](#) regarding an intermittent shortage of brand EpiPen, brand EpiPen Jr, and their authorized generics. Supply levels may continue to vary across wholesalers and pharmacies due to manufacturing delays.

As a reminder, to address this HHSC changed the preferred status of the brand products on May 23 to make product available without a non-preferred prior authorization. The brand products were non-preferred and changed to have no preferred status. Changes were reflected in the daily formulary file after Friday, May 18.

Brand NDC	Drug Name / Description	Previous Status	New Status
49502050002	EPIPEN 2-PAK 0.3 MG AUTO-INJCT	Non-Preferred	No PDL Status
49502050102	EPIPEN JR 2-PAK 0.15 MG INJCTR	Non-Preferred	No PDL Status

Generics will have no change in preferred status.

Generic NDC	Drug Name / Description	Status
49502010201	EPINEPHRINE 0.3 MG AUTO-INJECT	Preferred
49502010202	EPINEPHRINE 0.3 MG AUTO-INJECT	Preferred

Generic NDC	Drug Name / Description	Status
49502010101	EPINEPHRINE 0.15 MG AUTO-INJCT	Preferred
49502010102	EPINEPHRINE 0.15 MG AUTO-INJCT	Preferred

The FDA does not have a timeline for the resolution of the shortage. HHSC will announce when the shortage is over and products are readily available in the market. At that time the brand products will be returned to their non-preferred status.

Questions about this notice may be sent via email to vdp_formulary@hhsc.state.tx.us.